Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways by Pratheeshkumar, Poyil et al.
University of Kentucky
UKnowledge
Toxicology and Cancer Biology Faculty
Publications Toxicology and Cancer Biology
10-18-2012
Quercetin Inhibits Angiogenesis Mediated Human
Prostate Tumor Growth by Targeting VEGFR- 2
Regulated AKT/mTOR/P70S6K Signaling
Pathways
Poyil Pratheeshkumar
University of Kentucky, pratheeshkumar.poyil@uky.edu
Amit Budhraja
University of Kentucky, amit.budhraja@uky.edu
Young-Ok Son
University of Kentucky, young-ok.son@uky.edu
Xin Wang
University of Kentucky, xin.wang4@uky.edu
Zhuo Zhang
University of Kentucky, zhuo.zhang@uky.edu
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/toxicology_facpub
Part of the Medical Toxicology Commons
This Article is brought to you for free and open access by the Toxicology and Cancer Biology at UKnowledge. It has been accepted for inclusion in
Toxicology and Cancer Biology Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Pratheeshkumar, Poyil; Budhraja, Amit; Son, Young-Ok; Wang, Xin; Zhang, Zhuo; Ding, Songze; Wang, Lei; Hitron, Andrew; Lee,
Jeong-Chae; Xu, Mei; Chen, Gang; Luo, Jia; and Shi, Xianglin, "Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor
Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways" (2012). Toxicology and Cancer Biology Faculty
Publications. 3.
https://uknowledge.uky.edu/toxicology_facpub/3
Authors
Poyil Pratheeshkumar, Amit Budhraja, Young-Ok Son, Xin Wang, Zhuo Zhang, Songze Ding, Lei Wang,
Andrew Hitron, Jeong-Chae Lee, Mei Xu, Gang Chen, Jia Luo, and Xianglin Shi
Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated
AKT/mTOR/P70S6K Signaling Pathways
Notes/Citation Information
Published in PLoS One, v. 7, no. 10, p. 47516.
© Pratheeshkumar et al. This is an open-access article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Digital Object Identifier (DOI)
http://dx.doi.org/10.1371/journal.pone.0047516
This article is available at UKnowledge: https://uknowledge.uky.edu/toxicology_facpub/3
Quercetin Inhibits Angiogenesis Mediated Human
Prostate Tumor Growth by Targeting VEGFR- 2 Regulated
AKT/mTOR/P70S6K Signaling Pathways
Poyil Pratheeshkumar1, Amit Budhraja1, Young-Ok Son1, Xin Wang1, Zhuo Zhang1, Songze Ding1,
Lei Wang1, Andrew Hitron1, Jeong-Chae Lee1, Mei Xu2, Gang Chen2, Jia Luo2, Xianglin Shi1*
1Graduate Center for Toxicology, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America, 2Department of Internal Medicine, College
of Medicine, University of Kentucky, Lexington, Kentucky, United States of America
Abstract
Angiogenesis is a crucial step in the growth and metastasis of cancers, since it enables the growing tumor to receive oxygen
and nutrients. Cancer prevention using natural products has become an integral part of cancer control. We studied the
antiangiogenic activity of quercetin using ex vivo, in vivo and in vitro models. Rat aortic ring assay showed that quercetin at
non-toxic concentrations significantly inhibited microvessel sprouting and exhibited a significant inhibition in the
proliferation, migration, invasion and tube formation of endothelial cells, which are key events in the process of
angiogenesis. Most importantly, quercetin treatment inhibited ex vivo angiogenesis as revealed by chicken egg
chorioallantoic membrane assay (CAM) and matrigel plug assay. Western blot analysis showed that quercetin suppressed
VEGF induced phosphorylation of VEGF receptor 2 and their downstream protein kinases AKT, mTOR, and ribosomal protein
S6 kinase in HUVECs. Quercetin (20 mg/kg/d) significantly reduced the volume and the weight of solid tumors in prostate
xenograft mouse model, indicating that quercetin inhibited tumorigenesis by targeting angiogenesis. Furthermore,
quercetin reduced the cell viability and induced apoptosis in prostate cancer cells, which were correlated with the
downregulation of AKT, mTOR and P70S6K expressions. Collectively the findings in the present study suggest that quercetin
inhibits tumor growth and angiogenesis by targeting VEGF-R2 regulated AKT/mTOR/P70S6K signaling pathway, and could
be used as a potential drug candidate for cancer therapy.
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Introduction
Angiogenesis, the formation of new blood vessels from
preexisting blood vessels, is a crucial step in the growth,
progression, and metastasis of tumors [1,2], which enables the
growing tumor to receive oxygen and nutrients [3]. The
angiogenic process involves the activation, proliferation, and
migration of endothelial cells toward angiogenic stimuli produced
by the tumor [4]. Inhibition of angiogenesis is currently perceived
as one of the promising strategies in the treatment of cancer.
Angiogenesis involves a sequence of coordinated events initiated
by the expression of angiogenic factors with their subsequent
binding to its cognate receptors on endothelial cells. Vascular
endothelial growth factor (VEGF), the most important angiogenic
signal protein, that stimulates tumor neoangiogenesis by increasing
mitogenic and survival properties of vascular endothelial cells
[5,6]. The specific action of the VEGF on the endothelial cells is
mainly mediated by two types of receptor tyrosine kinases (RTKs),
VEGFR-1 and VEGFR-2. Of the two receptors, VEGFR-2 plays
a more important role in mediating the mitogenesis and
permeability of endothelial cells. Activation of VEGFR-2 con-
tributes to phosphorylation of multiple downstream signals
including ERK, JNK, PI3K, AKT, P70S6K and p38MAPK that
subsequently promote proliferation, migration, and tube formation
of endothelial cells [7].
The mammalian target of rapamycin (mTOR) is a protein
kinase of the PI3K/Akt signalling pathway with a central role in
the control of cell proliferation, survival, mobility and angiogen-
esis. Dysregulation of mTOR pathway has been found in many
human tumours; therefore, the mTOR pathway is considered an
important target for the development of new anticancer drugs [8].
One of the functions of Akt is phosphorylation and activation of
mTOR. Subsequently, activated mTOR regulates p70S6K
phosphorylation and activation [9]. The Akt-mTOR-p70S6K
signaling pathway has been considered not only a central
regulatory pathway of the protein translation involved in
regulating cell proliferation, growth, differentiation and survival,
but also a crucial step leading to angiogenesis in the neoplastic and
non-neoplastic process [10].
Natural products are a tremendous source of active therapeutic
agents, including anticancer agents. Cancer prevention using
natural products has become an integral part of cancer control.
Phytochemicals are potential novel leads for developing anti-
angiogenic drugs [11,12]. Flavonoids are polyphenolic substances,
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widely distributed in almost every food plant, that possess antiviral,
antimicrobial, anti-inflammatory, anti-allergic, anti-thrombotic,
antimutagenic, antineoplasic, and cytoprotective effects on differ-
ent cell types, both in animal and human models [13].
Epidemiologic studies have suggested that high consumption of
flavonoids may be associated with decreased risk of several types of
cancer [14]. Quercetin (Quer) (Fig. 1a) is found in a variety of
plant-based foods such as red onions, apples, tea (Camelia sinensis),
broccoli, capers, lovage, parsley, red grapes and a number of
berries [15]. The potential chemopreventive effects of quercetin
have been attributed to various mechanisms including its anti-
oxidative activity as well as its capacity to inhibit enzymes that
activate carcinogens, to modify signal transduction pathways, and
to interact with and regulate cell receptors and other proteins [16].
In the present study, we analyzed the effect of quercetin on the
inhibition of tumor specific angiogenesis in vivo as well as in vitro
models. We found that quercetin can inhibit VEGF induced
chemotactic migration, invasion, proliferation, and tube formation
of HUVECs by suppressing VEGFR-2-regulated AKT/mTOR/
P70S6K activation. Quercetin also blocks micro-vessel out growth
in rat aortic ring and vascular density in CAM. Moreover,
quercetin inhibits cancer growth and angiogenesis in human
prostate xenograft mouse model.
Materials and Methods
Ethics Statement
Animals were handled in strict accordance with good animal
practice as defined by Institutional Animal Care and Use
Committee (IACUC), University of Kentucky (Approval ID:
2011-0851). The study was conducted adhering to the institutions
guidelines for animal husbandry.
Chemicals and Reagents
Quercetin (.99% pure) was purchased from Sigma (St. Louis,
MO, USA), dissolved in DMSO, aliquoted, and stored at 220uC.
Bacteria-derived recombinant human VEGF (121 a.a.) was
purchased from ProSpec-Tany TechnoGene Ltd. (Ness Ziona,
Israel). Growth factor-reduced Matrigel was purchased from BD
Biosciences (Bedford, MA). The antibodies anti-AKT, anti-
mTOR, anti-p70S6K1, antipoly (ADP-ribose) polymerase
(PARP), phospho-specific anti-AKT (Ser473), anti-mTOR
(Ser2448), anti-p70S6K1 (Thr421/Ser424), and anti-VEGFR2
(Tyr1175) were purchased from Cell Signaling Technology
(Beverly, MA). The antibody against b-actin was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Highly specific
Figure 1. Quercetin inhibits the VEGF induced cell proliferation in HUVECs. (a) Chemical structure of quercetin. (b) Effect of quercetin on
HUVECs viability in culture. HUVECs (5000 cells/well) were plated in a 96 well titer plate with different concentrations of quercetin and incubated for
48 h. Relative cell viability was determined by MTT assay. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant
difference from untreated controls. (c) Quercetin inhibits the VEGF induced proliferation of endothelial cells. HUVECs (5000 cells/well) in 96-well flat
bottomed titer plate with different concentrations of quercetin and VEGF and incubated for 24 h. Relative cell proliferation was determined by MTT
assay. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes
a statistically significant difference from VEGF control.
doi:10.1371/journal.pone.0047516.g001
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quantitative sandwich ELISA kit for human VEGF was purchased
from RayBiotech (GA, USA).
Cell Lines and Cell Culture
Human umbilical vein endothelial cells (HUVECs) were
provided by Dr. Jia Luo (Department of Internal Medicine,
University of Kentucky College of Medicine, Lexington, KY)
and grown in Clonetics Endothelial Cell Growth Medium-2
(EGM-2; Lonza, Walkersville, MD) [17]. Human prostate
cancer (PC-3) cells were purchased from American Type
Culture Collection and cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS). HUVECs
and PC-3 cells were cultured at 37uC under a humidified 95%:
5% (v/v) mixture of air and CO2.
MTT Assay
The MTT assay was employed to determine the number of
viable cells in culture. Briefly, HUVECs or PC-3 cells were seeded
(5000 cells/well) in 96-well flat bottomed titer plate and incubated
for 24 h at 37uC in 5% CO2 atmosphere. Different dilutions of
quercetin were added and incubated further for 24 h. Before 4 h
completion of incubation, 10 ml MTT (5 mg/ml) was added [18].
The cultures were solubilized and spectrophotometric absorbance
was measured at 595 nm using a microtiter plate reader. The
number of viable cells was presented relative to untreated controls.
Cell Proliferation Assay
HUVECs were seeded (5000 cells/well) in 96-well flat
bottomed titer plate and incubated for 24 h at 37uC in 5%
CO2 atmosphere. EGM-2 (0.5% FBS) containing 10 ng/mL
Figure 2. Quercetin inhibits VEGF-induced migration, invasion, and tube formation of endothelial cells. (a) Quercetin inhibited HUVECs
migration. HUVECs were grown into wells of collagen coated 24 well plate dishes to 100% confluence. Cells were starved to inactivate cell
proliferation and then wounded by pipette tips. EGM-2 containing 0.5% FBS was added with or without 10 ng/mL VEGF and different dilutions of
quercetin. Migrated cells were quantified by manual counting. (b) Quercetin inhibited HUVECs invasion. HUVECs (105 cells/Transwell) along with the
indicated concentrations of quercetin were seeded into the upper compartment of invasion chambers. The bottom chambers were filled with EGM-2
supplemented with VEGF. After 24 h incubation, migrated cells were fixed, stained and quantified. (c) Quercetin inhibited the tube formation of
HUVECs. HUVECs in medium EGM-2 were seeded into the matrigel layer in 24–well plates with VEGF. Various dilutions of quercetin were added into
the wells and incubated for 24 h, cells were fixed, and tubular structures were photographed. Values are means 6 SD (mean of triplicate). *p,0.05
denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically significant difference from VEGF control.
doi:10.1371/journal.pone.0047516.g002
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VEGF with or without different dilutions of quercetin was
added and incubated for 24 h. Relative cell proliferation was
determined by MTT assay.
Wound-healing Migration Assay
HUVECs were grown into wells of collagen coated 24 well plate
dishes to 100% confluence. Cells were starved to inactivate cell
proliferation and then wounded by pipette tips. EGM-2 containing
0.5% FBS was added with or without 10 ng/mL VEGF and
different dilutions of quercetin. Images of the cells were taken after
24 h of incubation. Migrated cells were quantified manually, and
presented relative to untreated controls. Three independent
experiments were performed.
Figure 3. Quercetin inhibits ex vivo angiogenesis by CAM and matrigel plug assay and in vitro angiogenesis by rat aortic ring assay.
(a) Quercetin inhibits ex vivo angiogenesis in CAM assay. Fertile leghorn chicken eggs were candled on embryonic day 8; a small opening was made at
the top of the live eggs. Quercetin for treatment was mixed with 0.5% methyl cellulose in water and gently placed on the CAM. The eggs were
incubated for 48 h and photographed. Blood vessels density was quantified by Image J software and represented as a bar diagram. Values are means
6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically significant
difference from 20 and 40mmol/L quercetin. (b) Quercetin inhibits ex vivo angiogenesis in matrigel plug assay. Matrigel plug containg VEGF and
quercetin were implanted into the CAM at day 9 of fertilized chicken eggs. After 96 h of incubation, the matrigel plugs were taken out and dispersed
in PBS and incubated at 4uC overnight. Hemoglobin levels were determined using Drabkin’s reagent according to manufacturer instructions. Values
are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from untreated controls; #p,0.05 denotes a statistically
significant difference from VEGF control. (c) Quercetin inhibits microvessel outgrowth from the rat aortic ring. Dorsal aorta from a freshly sacrificed
Sprague–Dawley rat was taken out in a sterile manner and rinsed in ice cold PBS. It was then cut into ,1 mm long pieces using surgical blade. Each
ring was placed in a collagen pre-coated 96-well plate. VEGF, with or without different dilutions of quercetin, was added to the wells. On day 6, the
rings were analyzed by phase-contrast microscopy and microvessel outgrowths were quantified and photographed. Values are means6 SD (mean of
triplicate). *p,0.05 denotes a statistically significant difference from untreated controls.
doi:10.1371/journal.pone.0047516.g003
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Transwell Invasion Assay
Transwell invasion assay was performed as described previously
[19]. Briefly, HUVECs (105 cells/Transwell) along with the
indicated concentrations of quercetin were seeded into the upper
compartment of invasion chambers. The bottom chambers were
filled with 500 mL EGM-2 supplemented with 10 ng/mL VEGF.
After 24 h incubation, migrated cells were fixed with 3.7%
paraformaldehyde and stained with 0.5% crystal violet in 2%
ethanol. Membranes were washed and the dye was eluted with
10% acetic acid. Absorbance was measured at 595 nm using
a microtiter plate reader (Beckman coulter). The number of
invaded cells was presented relative to untreated controls.
Capillary-like Tube Formation Assay
HUVECs in medium EGM-2 were seeded into the matrigel
layer in 24–well plates at a density of 66104 cells/well along with
10 ng/ml VEGF. Various dilutions of quercetin were added into
the wells and incubated for 24 h at 37uC in 5% CO2 atmosphere.
Tube formation was examined and photographed using an
inverted microscope (20X) [20].
ELISA Assays for Secretion of VEGF
PC-3 cells (26105) were plated in 24-well plates and allowed to
attach by overnight incubation at 37uC. Cells were treated with
desired concentrations of quercetin for 24 h. Subsequently, the
culture medium was collected and used to determine secretion of
VEGF using commercially available kits according to the
manufacturers’ recommendations.
Rat Aortic Ring Assay
The rat aortic ring assay was used as the in vitro angiogenesis
study model [21]. Dorsal aorta from a freshly sacrificed Sprague–
Dawley rat was taken out in a sterile manner and rinsed in ice cold
PBS. It was then cut into ,1 mm long pieces using surgical blade.
Each ring was placed in a collagen pre-coated 96-well plate.
VEGF, with or without different dilutions of quercetin, was added
to the wells. On day 6, the rings were analyzed by phase-contrast
microscopy and microvessel outgrowths were quantified and
photographed [22]. The assay was scored from 0 (least positive)
to 5 (most positive) in a double-blind manner. Each data point was
assayed 6 times [23].
CAM Assay in Fertilized Chicken Eggs
The effect of quercetin on ex vivo angiogenesis was determined
by CAM assay. Briefly, fertile leghorn chicken eggs (Poultry
Breeding farm, University of Kentucky) were candled on
embryonic day 8; a small opening was made at the top of the
live eggs. Quercetin for treatment was mixed with 0.5% methyl
cellulose in water and gently placed on the CAM. The eggs were
incubated for 48 h and photographed. Blood vessels density was
quantified by Image J software and represented as a bar diagram.
Matrigel Plug Assay
Fertilized chicken eggs (Poultry Breeding farm, University of
Kentucky) were incubated at 37uC for 9 days, and angiogenesis
assay was performed as previously described [24]. In brief, VEGF
(100 ng) and quercetin (20 mg) were mixed with matrigel and
implanted into the CAM at day 9. After 96 h of incubation, the
tumor plugs were taken out and dispersed in PBS and incubated at
4uC overnight. Hemoglobin levels were determined using
Drabkin’s reagent (Sigma-Aldrich, St. Louis, MO) according to
manufacturer instructions.
Western Blot Analysis
To determine the effects of quercetin on the VEGFR2–
dependent mTOR signaling pathway, HUVECs were first starved
in serum-fee EGM-2 for 6 h, and then pretreated with or without
quercetin for 1 h, followed by the stimulation with 50 ng/mL of
VEGF for 10 min (for VEGFR2 activation) or 30 min (for mTOR
pathway kinase activation). To examine mTOR pathway in
prostate tumor cells, normal cultured PC-3 cells were directly
treated with indicated dilutions of quercetin for 6 h. The total
cellular samples were washed twice with ice-cold PBS and lysed in
1X NuPAGE LDS sample buffer supplemented with 50 mM
dithiothreitol. The protein concentration was determined using
Coomassie Protein Assay Reagent (Pierce, Rockford, IL). About
40 mg cellular proteins were separated using 6%–12% SDS-
polycrylamide gel and transferred to nitrocellulose membrane.
Membranes were blocked with 5% fat-free dry milk in 1X Tris-
buffered saline (TBS) and incubated with antibodies. Protein
bands were detected by incubating with horseradish peroxidase-
conjugated antibodies (Kirkegaard and Perry Laboratories,
Gaithersburg, MD) and visualized with enhanced chemilumines-
cence reagent (Perkin Elmer, Boston, MA).
For tissue sections, radioimmunoprecipitation assay (RIPA)
buffer was added to the sections and homogenized with electric
homogenizer. After incubation for 20 minutes on ice, samples
were centrifuged for 30 minutes at 12,000 rpm at 4uC and
Figure 4. Quercetin inhibits the activation of VEGFR2-mediated
signaling pathways in HUVECs. Quercetin suppressed the activa-
tion of VEGFR2 and their down stream AKT/mTOR/p70S6K pathway
triggered by VEGF in HUVECs. Proteins from different treatments was
tested by western blotting and probed with specific antibodies.
Experiments were repeated for three times.
doi:10.1371/journal.pone.0047516.g004
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supernatant was collected as total cell lysate. SDS-PAGE was
carried out as described previously [25].
Xenograft Human Prostate Tumor Mouse Model
Six week old male BALB/cA nude mice were purchased from
charles River Laboratories (Wilmington, MA). Animals were
housed in a specific pathogen-free room within the animal facilities
at the University of Kentucky, Lexington, KY. All animals were
allowed to acclimatize to their new environment for one week
prior to use and were handled according to the Institutional
Animal Care and Use, University of Kentucky. Mice were
randomly divided into 2 groups (5 animals/group). PC-3 cells
(56106 cells per mouse) were resuspended in serum-free RPMI-
1640 medium with matrigel basement membrane matrix (BD
Biosciences) at a 1:1 ratio (total volume: 100 mL) and then were
subcutaneously injected into the flanks of nude mice. After tumors
grew to about 100 mm3, mice were treated intraperitoneally with
or without quercetin (20 mg/kg/d). The body weight of each
mouse was recorded and tumor volume was determined by
Vernier caliper every day, following the formula of A6B260.52,
where A is the longest diameter of tumor and B is the shortest
diameter. After 16 d, the mice were killed by cervical dislocation
and solid tumors were removed.
Histology and Immunohistochemistry
Tumor tissues were fixed in 10% neutral-buffered formalin
for 24 hours, processed, and embedded in paraffin blocks. The
sections (5 mm) were blocked with 10% goat serum and
incubated with a rabbit anti-CD31 (1:100; Novus Biologicals
Inc, Littleton, CO) and mouse ant-CD34 (1:100; BD Pharmin-
gen Inc, San Diego, CA) antibodies for 24 h. The slides were
subsequently incubated for 30 min with biotinylated anti-rabbit/
anti-mouse secondary antibody (Vector laboratories, Burlin-
game, CA) and followed by incubation of Vectastain ABC Kit
(Vector Laboratories). Diaminobenzidine (Sigma) was used as
the chromagen and methyl green (Sigma) as the counterstain.
Statistics
The values were presented as means6 SD. Two-way analysis of
variance (ANOVA) and Student’s t test were used for statistical
analysis. p,0.05 was considered significantly different.
Figure 5. Quercetin induces cell apoptosis and inhibits the activation of AKT/mTOR/p70S6K pathway in prostate cancer cells. (a)
Quercetin inhibited VEGF secretion in prostate PC-3 cancer cells. VEGF level was estimated by ELISA method. Values are means 6 SD (mean of
triplicate). *p,0.05 denotes a statistically significant difference from untreated controls. (b) Quercetin inhibited cell viability of prostate PC-3 cancer
cells. Cell viability was quantified by MTT assay. Values are means6 SD (mean of triplicate). *p,0.05 denotes a statistically significant difference from
untreated controls. (c) Quercetin induced PC-3 cancer cell apoptosis by the cleaved-PARP analysis. PC-3 cells were treated with quercetin for 48 h,
and whole cell proteins were analysed by Western blotting with antipoly (ADP-ribose) polymerase (PARP). (d) Quercetin inhibited the activation of
AKT/mTOR/p70S6K pathway in PC-3 cells. Proteins from different treatments was tested by western blotting and probed with specific antibodies.
Experiments were repeated for three times.
doi:10.1371/journal.pone.0047516.g005
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Results
Effect of Quercetin Towards HUVECs Viability in Culture
Cell viability was determined by MTT assay. Effect of quercetin
on HUVECs viability in culture is shown in Figure 1b. At
concentrations of 10–40 mmol/L quercetion was found to be non-
toxic to HUVECs and these concentrations were used for further
in vitro experiments.
Quercetin Inhibits HUVECs Proliferation, Chemotactic
Migration, Invasion, and Tube Formation
VEGF plays an important role during neo-angiogenesis
through its mitogenic effect on endothelial cells [26]. HUVECs
showed very high rate of proliferation when stimulated with
VEGF. Quercetin treatment at concentrations of 10-40 mmol/L
significantly inhibited VEGF induced proliferation of HUVECs
(Fig. 1c).
Effect of quercetin on the chemotactic motility of HUVECs is
shown in Figure 2a. HUVECs migrated into the clear area when
stimulated with chemoattractant, VEGF. Quercetin significantly
inhibited the VEGF induced migration of endothelial cells in
a dose dependent manner and maximum inhibition of endothelial
cell migration was observed at 40 mmol/L and was almost similar
to that of zero hour incubation. This concentration is non-toxic as
is evident from MTT assay (Fig. 1b) and hence the inhibitory effect
could not be attributed to cytotoxic activity. HUVECs showed
a high invasive property through the collagen matrix when
stimulated with VEGF (Fig. 2b). Treatment of quercetin produced
a significant inhibition in the invasion of the collagen matrix by
HUVECs in a dose dependent manner. The tubular formation of
endothelial cells is also a key step of angiogenesis [27]. Treatment
of HUVECs with quercetin significantly inhibited tube formation
(Fig. 2c). Incubation of HUVECs on matrigel with VEGF resulted
in the formation of elongated and tube like structures. Quercetin
effectively reduced the width and length of endothelial tubes at 20
and 40 mmol/L.
Quercetin Inhibits ex vivo Angiogenesis in CAM Assay
CAM assay was used to determine the antiangiogenic effect of
quercetin ex vivo. CAM revealed highly vascularized structure in
the control group (Fig. 3a). Exposure to quercetin (20 and
40 mmol/egg) drastically reduced the vascular density. These
results confirmed the anti-angiogenic potential of quercetin
through an ex vivo assay.
Quercetin Inhibits ex vivo Angiogenesis in Matrigel Plug
Assay
To confirm the anti-angiogenesis effects of quercetin ex vivo,
matrigel plug assay was performed. As shown in Figure 3b,
quercetin (20 mg) significantly inhibited VEGF-induced angiogen-
esis in the matrigel plug, indicating quercetin effectively inhibited
angiogenesis ex vivo. Hemoglobin level was also significantly lower
Figure 6. Quercetin inhibits tumor growth in a xenograft mouse model. PC-3 cells were injected into 6-week old BALB/cA nude mice (56106
cells per mouse). After tumors grew to about 100 mm3, mice were treated intraperitoneally with or without quercetin (20 mg/kg/d). (a) Solid tumors
in the quercetin treated mice were significantly smaller than those in the control mice. Quercetin significantly reduced (b) tumor volume, and (c)
tumor weight, (d) but had no effect on the body weight of mice. Values are means 6 SD (mean of triplicate). *p,0.05 denotes a statistically
significant difference from untreated controls.
doi:10.1371/journal.pone.0047516.g006
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in the quercetin treated matrigel plug, further confirming their
antiangiogeneic potential.
Quercetin Inhibits Microvessel Outgrowth from the Rat
Aortic Ring
To study the inhibitory effect of quercetin on in vitro
angiogenesis, we performed aortic ring assay. VEGF can induce
microvessel outgrowth in rat aorta ring. As shown in Figure 3c,
quercetin at 20 and 40 mmol/L inhibited micro-vessel growth after
6 days incubation, indicating that quercetin inhibits angiogenesis
in vitro.
Quercetin Inhibits the Activation of VEGFR2-mediated
Signaling Pathways in Endothelial Cells
VEGFR2 binds with VEGF that activates various down-
stream signaling molecules responsible for endothelial cell
migration, proliferation, and survival. To understand the
molecular mechanism of quercetin-mediated anti-angiogenic
properties, we examined the signaling molecules and pathways
using western blotting assays. VEGF treatment strongly in-
creased the VEGFR2 phosphorylation at Ser1175 site, a reliable
marker for its activity. In our study, we found that phosphor-
ylation of VEGFR2 was suppressed by quercetin in a dose-
dependent manner (Fig. 4). Quercetin significantly suppressed
the activation of VEGFR2 downstream signaling molecules such
as AKT, mTOR, and p70S6K, which indicated that quercetin
inhibited angiogenesis through direct inhibition of VEGFR2 on
the surface of endothelial cells. Extensive down regulation of
phospho-AKT (Ser473), a well-known downstream target of
VEGFR2, was observed at 40 mM quercetin, however total
AKT levels remain unchanged (Fig. 4, upper panel western).
Next, we examined the expression of phospho-mTOR (Ser2448)
after quercetin exposure and the results in Figure 4 (lower panel
western) revealed that phospho-mTOR levels were also de-
creased together with phospho-AKT. Total mTOR levels were
unaltered. Furthermore, phospho-S6K (downstream target of
mTOR) was decreased in a dose- dependent exposure in
endothelial cells (Fig. 4, lower western). The concentrations of
quercetin used for the above experiments were found to be non-
toxic to endothelial cells (Fig. 1b), suggesting that the effect of
quercetin on endothelial cells were not through decrease in cell
viability. Collectively, the results described in this section
indicated that quercetin inhibited VEGF mediated angiogenesis
through VEGFR2 mediated pathway.
Figure 7. Quercetin inhibits tumor angiogenesis in vivo by suppressing AKT/mTOR/p70S6K pathway. (a) Quercetin inhibited the
activation of AKT/mTOR/p70S6K pathway in vivo. Proteins from tumor tissue was tested by western blotting and probed with specific antibodies.
Experiments were repeated for three times. Quercetin inhibited tumor angiogenesis as evident from (b) CD31 and (c) CD34 immunohistochemistry.
Tumor sections (5 mm) were incubated with a rabbit anti-CD31 and mouse anti-CD34 antibodies and were subsequently incubated with biotinylated
anti-rabbit/anti-mouse secondary antibody, followed by staining with Vectastain ABC Kit.
doi:10.1371/journal.pone.0047516.g007
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Quercetin Inhibits VEGF Secretion in PC-3 Cells
VEGF plays an important role in angiogenesis by promoting
endothelial cell proliferation, migration, and differentiation [28].
We determined the effect of quercetin on VEGF secretion and the
results are shown in Figure 5a. The quercetin treatment caused
a dose-dependent and statistically significant decrease in VEGF
secretion into the medium.
Quercetin Induces Cancer Cell Apoptosis and Inhibits
AKT/mTOR/P70S6K Pathway in PC-3 Prostate Cancer
Cells
Poly (ADP-ribose) polymerase (PARP) is a family of proteins
involved in cell death [29,30], and shown to be cleaved into 89-
and 24-kD fragments that contain the active site and the DNA-
binding domain of the enzyme, respectively, during drug induced
apoptosis in a variety of cells [31-33]. Quercetin significantly
decreased the PC-3 cell viability (Fig. 5b) and also induced tumor
cell apoptosis by detecting full length PARP (116 kDa) and its
large cleavage fragment (89 kDa) (Fig. 5c). This data suggest that
quercetin also have direct cytotoxic effects on cancer cells besides
its antiangiogenic effect on endothelial cells. To verify the
inhibitory effect of quercetin on PC-3 cell viability, we further
examined the effect of different concentrations of quercetin on the
phosphorylation of AKT, mTOR, and P70S6K. As shown in
Figure 5d, quercetin dramatically inhibited the phosphorylation of
AKT, mTOR, and P70S6K, but the total protein levels remain
unchanged, indicating that the AKT/mTOR pathway is also
a possible target of quercetin in tumor cells.
Quercetin Inhibits Tumor Angiogenesis and Tumor
Growth in vivo
We used a xenograft prostate tumor model to investigate the
effect of quercetin on tumor growth and angiogenesis. PC-3
prostate cancer cells were injected (56106 per mouse) into the 6-
week-old male BALB/cA nude mice. After the tumors had
developed (about 100 mm3), the mice were injected with or
without 20 mg/Kg/day quercetin (ip) every day (Fig. 6a). We
found that intraperitoneal administration of quercetin significantly
suppressed tumor volume (Fig. 6b) and tumor weight (Fig. 6c) but
had no effect on the body weight of mice (Fig. 6d). As shown in
Figure 6b, tumors in control group increased from 108.3167.35 to
551.66661.32 mm3, whereas tumors in quercetin-treated group
decreased from 101.7768.57 to 71.1662.65 mm3. The average
weight of tumors from the control group was 0.24260.04 gram
whereas the average weight in quercetin treated group was only
0.09960.01 gram, suggesting strong anti-tumor potential of
quercetin in xenograft mouse prostate tumor model.
To further investigate whether quercetin inhibited tumor
growth by suppressing tumor angiogenesis, we performed western
blot and immunohistochemical analysis of solid tumors (Fig. 7).
Tumors from quercetin treated animals showed a suppressed
activation of AKT, mTOR and P70S6K proteins (Fig. 7a). We
also observed a large number of CD31 (Fig. 7b) and CD34 (Fig. 7c)
positive cells in untreated control group whereas a small number
in quercetin treated group. All these observations indicate the
antiangiogenic efficacy of quercetin in vivo that strongly support the
above ex vivo and in vitro studies.
Discussion
Tumors can grow up to ,2 mm size without requirement of
blood supply as diffusion is sufficient at this level to support the
removal of wastes from and supply of nutrients to tumor cells.
Therefore, angiogenesis process could be an important target to
suppress tumor growth and metastasis. Angiogenesis is required at
almost every step of tumor progression and metastasis, and tumor
vasculature has been identified as strong prognostic marker for
tumor grading [34]. So inhibition of angiogenesis induced by
tumor and metastasis cells is a promising therapeutic strategy for
cancer. Several antiangiogenic strategies have been developed to
inhibit tumor growth by targeting different components of tumor
angiogenesis. Many phytochemicals could have a tremendous
potential as antiangiogenic agents to check the cancer develop-
ment and metastasis [34].
Invasion, migration, proliferation and tube formation of
endothelial cells are important steps in the angiogenic cascade.
Treatment with quercetin dose dependently inhibited the collagen
matrix invasion, chemotactic migration, proliferation and tube
formation of HUVECs in vitro. Among many angiogenesis assays,
the CAM assay is well established and widely used as a model to
examine anti-angiogenesis [35]. In the present study, we
demonstrated that quercetin significantly inhibited neovascular-
ization ex vivo in CAM assay and matrigel plug assay. Quercetin
also exhibited cytotoxicity and induced apoptosis towards prostate
tumor cells (PC-3). We found that intraperitoneal administration
of quercetin significantly suppressed volume and weight of tumors,
but had no effect on the body weight of mice. Immunohistochem-
ical data also showed that the expressions of endothelial cell
markers, CD31 and CD34 were markedly less in tumor sections of
quercetin treated animals.
Several angiogenic activators and inhibitors have been identi-
fied. Amongst the many proangiogenic mechanisms, the vascular
endothelial growth factor (VEGF) signaling pathway has been
implicated as the key regulator of tumor neovascularization [36].
VEGF is thus an attractive therapeutic target. VEGF has been
demonstrated to have a major association with initiating the
process of angiogenesis through regulating proliferation, migra-
tion, and differentiation of endothelial cells [37]. Here in our
study, quercetin significantly inhibited the level of VEGF in PC-3
cells.
The mammalian target of rapamycin (mTOR) has been
identified as a key player in tumor growth, metastasis and
angiogenesis [38]. Dysregulation of mTOR pathway has been
found in many human tumors; therefore, the mTOR pathway is
considered an important target for the development of new
anticancer drugs [8]. AKT is a serine/threonine kinase that plays
a central role in a range of cellular functions including cell growth,
proliferation, migration, protein synthesis, and angiogenesis
[39,40]. P70S6K kinase (p70S6K), a downstream of AKT, plays
an important role in regulating tumor microenvironment and
angiogenesis [41]. Recently, AKT/mTOR/p70S6K signaling has
been identified as a novel, functional mediator in angiogenesis
[23]. Treatment with quercetin showed a sharp decrease in the
phosphorylation of mTOR and p70S6K, and its upstream kinase,
AKT, suggesting that quercetin suppresses tumor angiogenesis by
inhibiting VEGFR2 and blocking its multiple downstream
signaling components. In conclusion, the present study shows that
quercetin is a potent inhibitor of angiogenesis in vitro, ex vivo and in
vivo. Quercetin treatment inhibited the activation of VEGF-R2
and thereby suppressed the AKT/mTOR/P70S6K mediated
angiogenesis signaling pathways.
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